Who are Droperidol Injectable Product's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risperidone long acting injectables, Oral Risperidone, Paliperdidone ER, Antipsychotic Maintenance, Comparison of Risperidone and Aripiprazole, OLA group: Olanzapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/droperidol-injectable-product.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Droperidol Injectable Product — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Droperidol Injectable Product (Droperidol Injectable Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Butyrophenone antipsychotic. Area: Psychiatry / Acute Care.

phase 3 Butyrophenone antipsychotic Dopamine D2 receptor Psychiatry / Acute Care Small molecule Live · refreshed every 30 min

Target snapshot

Droperidol Injectable Product (Droperidol Injectable Product) — Mercy Health Ohio. Droperidol is a butyrophenone antipsychotic that blocks dopamine receptors in the central nervous system, reducing agitation and providing antiemetic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Droperidol Injectable Product TARGET	Droperidol Injectable Product	Mercy Health Ohio	phase 3	Butyrophenone antipsychotic	Dopamine D2 receptor
Risperidone long acting injectables	Risperidone long acting injectables	Janssen Korea, Ltd., Korea	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Oral Risperidone	Oral Risperidone	Zogenix, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Paliperdidone ER	Paliperdidone ER	Janssen Korea, Ltd., Korea	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Antipsychotic Maintenance	Antipsychotic Maintenance	University College, London	marketed	Antipsychotic (typical or atypical)	Dopamine D2 receptor; serotonin 5-HT2A receptor (varies by specific agent)
Comparison of Risperidone and Aripiprazole	Comparison of Risperidone and Aripiprazole	Vanderbilt University Medical Center	marketed	Second-generation antipsychotic (atypical antipsychotic)	Dopamine D2 receptor (risperidone: antagonist; aripiprazole: partial agonist); serotonin 5-HT2A receptor (risperidone)
OLA group: Olanzapine	OLA group: Olanzapine	The Guthrie Clinic	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Butyrophenone antipsychotic class)

Mercy Health Ohio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Droperidol Injectable Product — Competitive Intelligence Brief. https://druglandscape.com/ci/droperidol-injectable-product. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing